A role for G-CSF and GM-CSF in nonmyeloid cancers

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 737-746

  Aliper, Alexander M ^a   Frieden Korovkina, Victoria P ^b   Buzdin, Anton ^a,c,d   Roumiantsev, Sergey A ^a,e,f   Zhavoronkov, Alex ^a,f,g  

^a Federal Research Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^b HiBiotechnology LLC Wellman   (United States)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d First Oncology Research and Advisory Center   (Russian Federation)

^e PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^f MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^g The Biogerontology Research Foundation   (United Kingdom)

Author keywords

Bladder; Bone; Cancer; Colorectal; G CSF; Glioma; GM SF; Lung; Melanoma; Metastasis; Prostate

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CANCER THERAPY; COLORECTAL CANCER; DRUG EFFICACY; GLIOMA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SOLID TUMOR; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84910037418     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.239     Document Type: Article

References (77)

1. Fleetwood, A. J., A. D. Cook, and J. A. Hamilton . 2005. Functions of granulocyte-macrophage colony-stimulating factor. Crit. Rev. Immunol. 25:405-428.
2. Shibasaki, T., N. Katayama, K. Ohishi, A. Fujieda, F. Monma, K. Nishi, et al. 2007. IL-3 cannot replace GM-CSF in inducing human monocytes to differentiate into langerhans cells. Int. J. Oncol. 30:549-555.
3. Metcalf, D. 2010. The colony-stimulating factors and cancer. Nat. Rev. Cancer 10:425-434.
4. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, et al. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12:560-567.
5. El-Behi, M., B. Ciric, H. Dai, Y. Yan, M. Cullimore, F. Safavi, et al. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12:568-575.
6. Tamada, T., E. Honjo, Y. Maeda, T. Okamoto, M. Ishibashi, M. Tokunaga, et al. 2006. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proc. Natl Acad. Sci. USA 103:3135-3140.
7. Hansen, G., T. R. Hercus, B. J. McClure, F. C. Stomski, M. Dottore, J. Powell, et al. 2008. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134:496-507.
8. Hercus, T. R., D. Thomas, M. A. Guthridge, P. G. Ekert, J. King-Scott, M. W. Parker, et al. 2009. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114:1289-1298.
9. Hercus, T. R., S. E. Broughton, P. G. Ekert, H. S. Ramshaw, M. Perugini, M. Grimbaldeston, et al. 2012. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors 30:63-75.
10. Hamilton, J. A. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8:533-544.
11. Kaushansky, K. 2006. Lineage-specific hematopoietic growth factors. N. Engl. J. Med. 354:2034-2045.
12. Valdembri, D., G. Serini, A. Vacca, D. Ribatti, and F. Bussolino . 2002. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 16:225-227.
13. Zgheib, A., S. Lamy, and B. Annabi . 2013. Epigallocatechin-gallate targeting of membrane type-1 matrix metalloproteinase-mediated Src and JAK/STAT3 signalling inhibits transcription of colony stimulating factors-2 and -3 in mesenchymal stromal cells. J. Biol. Chem. 288:13378-13386.
14. West, N. R., J. I. Murray, and P. H. Watson . 2013. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 33:1485-1494.
15. Levina, V., A. M. Marrangoni, R. DeMarco, E. Gorelik, and A. E. Lokshin . 2008. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3:e3077.
16. Banerjee, A., P. Qian, Z. S. Wu, X. Ren, M. Steiner, N. M. Bougen, et al. 2012. Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. J. Biol. Chem. 287:42502-42515.
17. Izumiya, M., A. Kabashima, H. Higuchi, T. Igarashi, G. Sakai, H. Iizuka, et al. 2012. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 32:3847-3853.
18. Shaked, Y., T. Tang, J. Woloszynek, L. G. Daenen, S. Man, P. Xu, et al. 2009. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 69:7524-7528.
19. Langenberg, M. H., M. W. Nijkamp, J. M. Roodhart, N. Snoeren, T. Tang, Y. Shaked, et al. 2010. Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: a potential role for G-CSF. Cancer Biol. Ther. 9:743-748.
20. Okazaki, T., S. Ebihara, M. Asada, A. Kanda, H. Sasaki, and M. Yamaya . 2006. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18:1-9.
21. Shojaei, F., X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, et al. 2009. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106:6742-6747.
22. Phan, V. T., X. Wu, J. H. Cheng, R. X. Sheng, A. S. Chung, G. Zhuang, et al. 2013. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc. Natl Acad. Sci. USA 110:6079-6084.
23. Lammel, V., C. Stoeckle, B. Padberg, R. Zweifel, D. L. Kienle, W. H. Reinhart, et al. 2012. Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. Lung Cancer 76:493-495.
24. Fukutomi, T., M. Kohno, Y. Izumi, M. Watanabe, Y. Hayashi, and H. Nomori . 2012. Pulmonary pleomorphic carcinoma producing granulocyte-macrophage colony-stimulating factor: report of a case. Surg. Today 42:288-291.
25. Bahar, B., B. Acedil Ayc Iota, U. Çoşkun, S. Büyükberber, M. Benekli, and R. Yildiz . 2010. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis. Asian Pac. J. Cancer Prev. 11:709-712.
26. Shalom, G., N. Sion-Vardy, J. Dudnik, and S. Ariad . 2010. Leukemoid reaction in lung cancer patients. Isr. Med. Assoc. J. 12:255-256.
27. Granger, J. M., and D. P. Kontoyiannis . 2009. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 115:3817-4041.
28. Jardin, F., M. Vasse, M. Debled, S. Dominique, P. Courville, F. Callonnec, et al. 2005. Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma. Am. J. Hematol. 80:243-245.
29. Stathopoulos, G. P., A. Armakolas, T. Tranga, H. Marinou, J. Stathopoulos, and H. Chandrinou . 2011. Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. Oncol. Rep. 25:1541-1544.
30. Chen, C., C. A. Duckworth, Q. Zhao, D. M. Pritchard, J. M. Rhodes, and L. G. Yu . 2013. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin. Cancer Res. 19:1693-1704.
31. Younos, I., M. Donkor, T. Hoke, A. Dafferner, H. Samson, S. Westphal, et al. 2011. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int. Immunopharmacol. 11:816-826.
32. Bhattacharjee, A., W. G. Richards, J. Staunton, C. Li, S. Monti, P. Vasa, et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98:13790-13795.
33. Kowanetz, M., X. Wu, J. Lee, M. Tan, T. Hagenbeek, X. Qu, et al. 2010. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl Acad. Sci. USA 107:21248-21255.
34. Wang, J., L. Yao, S. Zhao, X. Zhang, J. Yin, Y. Zhang, et al. 2012. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol. Ther. 13:389-400.
35. Revoltella, R. P., M. Menicagli, and D. Campani . 2012. Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 57:347-359.
36. Karcher, S., H. H. Steiner, R. Ahmadi, S. Zoubaa, G. Vasvari, H. Bauer, et al. 2006. Different angiogenic phenotypes in primary and secondary glioblastomas. Int. J. Cancer 118:2182-2189.
37. Brantley, E. C., L. B. Nabors, G. Y. Gillespie, Y. H. Choi, C. A. Palmer, K. Harrison, et al. 2008. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin. Cancer Res. 14:4694-4704.
38. Weissenberger, J., S. Loeffler, A. Kappeler, M. Kopf, A. Lukes, T. A. Afanasieva, et al. 2004. IL-6 is required for glioma development in a mouse model. Oncogene 23:3308-3316.
39. Niola, F., C. Evangelisti, L. Campagnolo, S. Massalini, M. C. Buè, A. Mangiola, et al. 2006. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5:174-179.
40. Jung, K. H., K. Chu, S. T. Lee, S. J. Kim, D. I. Sinn, S. U. Kim, et al. 2006. Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res. 1073-1074:190-201.
41. Ohki, Y., B. Heissig, Y. Sato, H. Akiyama, Z. Zhu, D. J. Hicklin, et al. 2005. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J. 19:2005-2007.
42. Curran, C. S., M. D. Evans, and P. J. Bertics . 2011. GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J. Immunol. 187:1254-1263.
43. Gabrusiewicz, K., A. Ellert-Miklaszewska, M. Lipko, M. Sielska, M. Frankowska, and B. Kaminska . 2011. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS ONE 6:e23902.
44. Kucerova, L., M. Matuskova, K. Hlubinova, V. Altanerova, and C. Altaner . 2010. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 9:129.
45. Raychaudhuri, B., P. Rayman, J. Ireland, J. Ko, B. Rini, E. C. Borden, et al. 2011. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 13:591-599.
46. Smith, K. E., S. Fritzell, W. Badn, S. Eberstål, S. Janelidze, E. Visse, et al. 2009. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Int. J. Cancer 124:630-637.
47. Smith, K. E., S. Janelidze, E. Visse, W. Badn, L. Salford, P. Siesjö, et al. 2007. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int. J. Cancer 120:75-80.
48. Mariani, C. L., D. Rajon, F. J. Bova, and W. J. Streit . 2007. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. J. Neurooncol. 85:231-240.
49. Welte, K., E. Platzer, L. Lu, J. L. Gabrilove, E. Levi, R. Mertelsmann, et al. 1985. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc. Natl Acad. Sci. USA 82:1526-1530.
50. Tachibana, M., A. Miyakawa, A. Uchida, M. Murai, K. Eguchi, K. Nakamura, et al. 1997. Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder. Br. J. Cancer 75:1489-1496.
51. Chakraborty, A., S. M. White, and S. Guha . 2006. Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. Urology 68:208-213.
52. Chakraborty, A., and S. Guha . 2007. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 69:1210-1215.
53. Wetzler, M., Z. Estrov, M. Talpaz, A. Markowitz, J. U. Gutterman, and R. Kurzrock . 1993. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J. Intern. Med. 234:417-420.
54. Perez, F. A., C. L. Fligner, and E. Y. Yu . 2009. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. J. Clin. Oncol. 27:e215-e217.
55. Turalic, H., F. D. Deamant, and J. H. Reese . 2006. Paraneoplastic production of granulocyte colony-stimulating factor in a bladder carcinoma. Scand. J. Urol. Nephrol. 40:429-432.
56. Kitayama, S., Y. Fujii, and K. Kihara . 2004. Urothelial cancer producing granulocyte colony-stimulating factor: possible induction of splenomegaly. Urology 63:377-378.
57. Ueno, M., S. Ban, T. Ohigashi, T. Nakanoma, S. Nonaka, R. Hirata, et al. 2000. Simultaneous production of granulocyte colony-stimulating factor and parathyroid hormone-related protein in bladder cancer. Int. J. Urol. 7:72-75.
58. Sanchez-Carbayo, M., N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo . 2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24:778-789.
59. Lee, J. S., S. H. Leem, S. Y. Lee, S. C. Kim, E. S. Park, S. B. Kim, et al. 2010. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28:2660-2667.
60. Theano, T., S. Pelagia, N. Konstantinos, K. Petros, B. Alfred, D. Konstantinos, et al. 2002. Lymphocyte activation by granulocyte macrophage-colony stimulating factor in human bladder cancer. J. Exp. Ther. Oncol. 2:153-157.
61. Wu, Q., R. Mahendran, and K. Esuvaranathan . 2003. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin. Cancer Res. 9:4522-4528.
62. Gofrit, O. N., K. C. Zorn, S. Shikanov, and G. D. Steinberg . 2010. Marker lesion experiments in bladder cancer-what have we learned? J. Urol. 183:1678-1684.
63. Demirci, U., U. Coskun, B. Sancak, B. Ozturk, B. Bahar, M. Benekli, et al. 2009. Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac. J. Cancer Prev. 10:1021-1024.
64. Urdinguio, R. G., A. F. Fernandez, A. Moncada-Pazos, C. Huidobro, R. M. Rodriguez, C. Ferrero, et al. 2013. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 73:395-405.
65. Matsuda, A., K. Sasajima, T. Matsutani, H. Maruyama, M. Miyamoto, T. Yokoyama, et al. 2009. Aggressive undifferentiated colon carcinoma producing granulocyte-colony stimulating factor: report of a case. Surg. Today 39:990-993.
66. Fujiwara, Y., O. Yamazaki, S. Takatsuka, R. Kaizaki, and T. Inoue . 2011. Granulocyte colony-stimulating factor-producing ascending colon cancer as indicated by histopathological findings: report of a case. Osaka City Med. J. 57:79-84.
67. Davis, J. L., R. T. Ripley, T. L. Frankel, I. Maric, J. N. Lozier, and S. A. Rosenberg . 2010. Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Res. 20:326-329.
68. Schniewind, B., M. Christgen, A. Hauschild, R. Kurdow, H. Kalthoff, and H. J. Klomp . 2005. Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line. Cancer Biol. Ther. 4:23-27.
69. Moon, H. W., T. Y. Kim, B. R. Oh, S. M. Hwang, J. Kwon, J. L. Ku, et al. 2012. Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cells. Korean J. Hematol. 47:219-224.
70. Roda, J. M., Y. Wang, L. A. Sumner, G. S. Phillips, C. B. Marsh, and T. D. Eubank . 2012. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J. Immunol. 189:3168-3177.
71. Grotz, T. E., L. Kottschade, E. S. Pavey, S. N. Markovic, and J. W. Jakub . 2013. Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma: a Single-center Study. Am. J. Clin. Oncol. Epub ahead of print.
72. Meyer, C., A. Sevko, M. Ramacher, A. V. Bazhin, C. S. Falk, W. Osen, et al. 2011. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108:17111-17116.
73. Obermueller, E., S. Vosseler, N. E. Fusenig, and M. M. Mueller . 2004. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 64:7801-7812.
74. Ma, Y., D. Liang, J. Liu, K. Axcrona, G. Kvalheim, K. E. Giercksky, et al. 2012. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol. 33:967-978.
75. Dai, J., Y. Lu, C. Yu, J. M. Keller, A. Mizokami, J. Zhang, et al. 2010. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res. 70:5014-5023.
76. Park, B. K., H. Zhang, Q. Zeng, J. Dai, E. T. Keller, T. Giordano, et al. 2007. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 13:62-69.
77. Altundag, K., O. Altundag, E. T. Elkiran, M. Cengiz, and Y. Ozisik . 2004. Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. Med. Hypotheses 63:56-58.